Rasagiline is a novel selective irreversible monoamine oxidase-B (MAO-B) inhibitor recently introduced for the symptomatic treatment of Parkinson disease. Like other propargylamines rasagiline has also shown neuroprotective effects independent of MAO-B-inhibition in various in vitro and in vivo models. The present study was performed to test the potential of rasagiline as a disease-modifying agent in multiple system atrophy (MSA) using a transgenic mouse model previously described by our group. (PLP)-alpha-synuclein transgenic mice featuring glial cytoplasmic inclusion pathology underwent 3-nitropropionic acid intoxication to model full-blown MSA-like neurodegeneration. Two doses of rasagiline were used (0.8 and 2.5 mg/kg) for a treatment period of 4 weeks. Rasagiline-treated animals were compared to placebo saline-treated mice by evaluation of motor behaviour and neuropathology. Motor behavioural tests including pole test, stride length test and general motor score evaluation showed improvements in motor deficits associated with 2.5 mg/kg rasagiline therapy. Immunohistochemistry and histology showed significant reduction of 3-NP-induced neuronal loss in striatum, substantia nigra pars compacta, cerebellar cortex, pontine nuclei and inferior olives of MSA mice receiving 2.5 mg/kg rasagiline. The results of the study indicate that rasagiline confers neuroprotection in a transgenic mouse model of MSA and may therefore be considered a promising disease-modifying candidate for human MSA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.expneurol.2007.11.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A POCIS-based approach for the monitoring of pharmaceuticals in wastewater treatment plants: Calibration and deployment challenges.
Environ Pollut
January 2025
Department of Analytical and Applied Chemistry, School of Engineering, IQS-Universitat Ramon Llull, Via Augusta 390, 08017, Barcelona, Spain. Electronic address:
Article Synopsis
- The study investigates the use of Polar Organic Chemical Integrative Samplers (POCIS) as a more effective method for monitoring pharmaceutical residues in wastewater compared to traditional grab sampling.
- POCIS allows for continuous sampling over days or weeks, providing more representative data, though challenges remain in obtaining precise quantitative results due to calibration needs.
- The research successfully identifies and calibrates sampling rates for 49 pharmaceuticals in a wastewater treatment plant near Barcelona, yielding high concentrations of specific compounds, thus establishing a methodology for better environmental monitoring of pharmaceuticals.
Serotonin Syndrome in Parkinson's Disease: Don't Get It Confused by a Tremor.
Cureus
November 2024
Intermediate Care Unit, Unidade Local de Saúde do Alto Minho, Viana do Castelo, PRT.
Serotonin syndrome (SS) is a potentially life-threatening condition caused by excessive serotonergic activity, often due to drug interactions. It classically manifests with autonomic and neuromuscular hyperactivity and by mental status changes that might include restlessness, delirium, and agitation. We present a case of a 76-year-old patient with Parkinson's disease with SS triggered by interaction between rasagiline and buspirone.
View Article and Find Full Text PDFCosts Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications.
Neurology
November 2024
From The Center for the Advancement of Team Science, Analytics, and Systems Thinking in Health Services and Implementation Science Research (CATALYST) (A.V.G.), College of Medicine, and Department of Neurology (C.C.L., K.K., J.F.B.), Division of Health Services Research, Wexner Medical Center, The Ohio State University, Columbus; Department of Epidemiology and Biostatistics (E.L.R.), Michigan State University, East Lansing; and Department of Neurology (B.C.C.), University of Michigan, Ann Arbor.
Article Synopsis
- A study analyzed medication cost trends for five common neurological conditions from 2012 to 2021, focusing on out-of-pocket (OOP) and total costs for patients.
- The research found significant increases in OOP costs, particularly a 217% rise for MS medications, while generic medications led to notable decreases in costs for other conditions after their introduction.
- The findings suggest that using generic medications can reduce costs, except for MS, indicating a need for policy interventions like cost caps to manage rising expenses.
Prominent Neuroprotective Potential of Indole-2--methylpropargylamine: High Affinity and Irreversible Inhibition Efficiency towards Monoamine Oxidase B Revealed by Computational Scaffold Analysis.
Pharmaceuticals (Basel)
September 2024
Laboratory for the Computational Design and Synthesis of Functional Materials, Division of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, 10000 Zagreb, Croatia.
: Monoamine oxidases (MAO) are flavoenzymes that metabolize a range of brain neurotransmitters, whose dysregulation is closely associated with the development of various neurological disorders. This is why MAOs have been the central target in pharmacological interventions for neurodegeneration for more than 60 years. Still, existing drugs only address symptoms and not the cause of the disease, which underlines the need to develop more efficient inhibitors without adverse effects.
View Article and Find Full Text PDFDesign, Synthesis, Molecular Docking, Pharmacokinetic Properties, and Molecular Dynamics Simulation of Sulfonyl Derivatives of Benzimidazole against Parkinson's Disease.
Curr Med Chem
October 2024
Department of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India.
Article Synopsis
- Parkinson's disease (PD) is a rapidly increasing global health issue with no cure, prompting the need for new drug development.
- The study focused on synthesizing and testing sulfonyl derivatives of benzimidazole as potential treatments by targeting monoamine oxidase B (MAO-B) using molecular docking techniques.
- Results showed that two synthesized compounds exhibited strong binding affinities, suggesting they could be promising candidates for effective PD therapies compared to existing drugs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!